Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-12-17 4:00 pm Sale |
2024-12-13 | 13D | NewAmsterdam Pharma Company N.V. NAMS |
Forbion Capital Fund IV Cooperatief U.A. | 11,123,614 10.400% |
-696,949 (-5.90%) |
Filing History |
| 2024-11-15 4:29 pm Sale |
2024-11-13 | 13D | NewAmsterdam Pharma Company N.V. NAMS |
Forbion Capital Fund IV Cooperatief U.A. | 11,820,563 12.800% |
-10,898 (-0.09%) |
Filing History |
| 2024-11-14 07:00 am Sale |
2024-09-30 | 13G | Replimune Group, Inc. REPL |
Forbion Capital Fund IV Cooperatief U.A. | 5,795,364 5.800% |
-335,715 (-5.48%) |
Filing History |
| 2023-07-07 5:06 pm Purchase |
2023-06-05 | 13D | NewAmsterdam Pharma Company N.V. NAMS |
Forbion Capital Fund IV Cooperatief U.A. | 11,831,461 14.500% |
3,589,061 (+43.54%) |
Filing History |
| 2023-07-07 5:00 pm Purchase |
2022-11-22 | 13D | NewAmsterdam Pharma Company N.V. NAMS |
Forbion Capital Fund IV Cooperatief U.A. | 8,242,400 10.100% |
8,242,400 (New Position) |
Filing History |
| 2022-02-11 09:20 am Purchase |
2021-12-31 | 13G | Achilles Therapeutics plc ACHL |
Forbion Capital Fund IV Cooperatief U.A. | 2,390,050 5.890% |
2,390,050 (New Position) |
Filing History |
| 2021-02-16 06:38 am Purchase |
2020-12-31 | 13G | Replimune Group, Inc. REPL |
Forbion Capital Fund IV Cooperatief U.A. | 6,131,079 13.490% |
6,131,079 (New Position) |
Filing History |